Windtree therapeutics, inc. (windtree) expanded access policy

Expanded access is a process regulated by the United States Food and Drug Administration (FDA) which allows pharmaceutical companies to provide investigational products to patients with serious, life-threatening diseases or conditions and who cannot participate in a clinical study.

Windtree is not currently offering expanded access to our investigational products. However, Windtree will periodically review its expanded access policy. For additional information about this policy, please contact [email protected] Responses will be provided within approximately 5 business days.